Key statistics
As of last trade SpringWorks Therapeutics Inc (SWTX:NSQ) traded at 38.80, -28.04% below its 52-week high of 53.92, set on Mar 08, 2024.
52-week range
Short selling activityProvided by S&P Global Market Intelligence
Open | 36.36 |
---|---|
High | 39.61 |
Low | 36.24 |
Bid | 38.82 |
Offer | 38.87 |
Previous close | 36.30 |
Average volume | 2.12m |
---|---|
Shares outstanding | 74.27m |
Free float | 72.08m |
P/E (TTM) | -- |
Market cap | 2.70bn USD |
EPS (TTM) | -3.89 USD |
Data delayed at least 15 minutes, as of Nov 22 2024 19:50 GMT.
More ▼
- SpringWorks Therapeutics to Participate in the Jefferies London Healthcare Conference
- SpringWorks Therapeutics Reports Third Quarter 2024 Financial Results and Recent Business Highlights
- SpringWorks Therapeutics Announces Mirdametinib Data to be Presented at the 2024 Society for Neuro-Oncology (SNO) Annual Meeting
- SpringWorks Therapeutics Announces Publication of the Pivotal Phase 2b ReNeu Trial Evaluating Mirdametinib in Adults and Children with NF1-PN in the Journal of Clinical Oncology
- SpringWorks Therapeutics Announces Long-Term Efficacy and Safety Data from Phase 3 DeFi Trial of OGSIVEO® (nirogacestat) in Adults with Desmoid Tumors to be Presented at the Connective Tissue Oncology Society (CTOS) 2024 Annual Meeting
- SpringWorks Therapeutics to Participate in Guggenheim’s Inaugural Healthcare Innovation Conference
- SpringWorks Therapeutics to Report Third Quarter 2024 Financial Results on Tuesday, November 12, 2024
- FDA Grants Priority Review to SpringWorks Therapeutics’ New Drug Application for Mirdametinib for the Treatment of Adults and Children with NF1-PN
- SpringWorks Therapeutics Reports Second Quarter 2024 Financial Results and Recent Business Highlights
- SpringWorks Therapeutics Appoints Dr. Martin Mackay to its Board of Directors
More ▼